[1] L.H. Calabrese, S. Rose-John, IL-6 biology: Implications for clinical targeting in rheumatic disease, Nat. Rev. Rheumatol. 10 (2014) 720–727. https://doi.org/10.1038/nrrheum.2014.127.
[2] E.H. Choy, F. De Benedetti, T. Takeuchi, M. Hashizume, M.R. John, T. Kishimoto, Translating IL-6 biology into effective treatments, Nat. Rev. Rheumatol. 16 (2020) 335–345. https://doi.org/10.1038/s41584-020-0419-z.
[3] M. Sheppard, F. Laskou, P.P. Stapleton, S. Hadavi, B. Dasgupta, Tocilizumab (actemra), Hum. Vaccines Immunother. 13 (2017) 1972–1988. https://doi.org/10.1080/21645515.2017.1316909.
[4] J. Wolf, S. Rose-John, C. Garbers, Interleukin-6 and its receptors: a highly regulated and dynamic system, Cytokine. 70 (2014) 11–20. https://doi.org/10.1016/j.cyto.2014.05.024.
[5] J.M. Sanders, M.L. Monogue, T.Z. Jodlowski, J.B. Cutrell, Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review, JAMA - J. Am. Med. Assoc. 323 (2020) 1824–1836. https://doi.org/10.1001/jama.2020.6019.
[6] A. Yarmohammadi, M. Yarmohammadi, S. Fakhri, H. Khan, Targeting pivotal inflammatory pathways in COVID-19: A mechanistic review, Eur. J. Pharmacol. 890 (2021) 173620. https://doi.org/10.1016/j.ejphar.2020.173620.
[7] L. De Stefano, F. Bobbio-Pallavicini, A. Manzo, C. Montecucco, S. Bugatti, A “Window of Therapeutic Opportunity” for Anti-Cytokine Therapy in Patients With Coronavirus Disease 2019, Front. Immunol. 11 (2020). https://doi.org/10.3389/fimmu.2020.572635.
[8] S. Khiali, E. Khani, T. Entezari-Maleki, A Comprehensive Review of Tocilizumab in COVID-19 Acute Respiratory Distress Syndrome, J. Clin. Pharmacol. 60 (2020) 1131–1146. https://doi.org/10.1002/jcph.1693.
[9] Y. Tang, J. Liu, D. Zhang, Z. Xu, J. Ji, C. Wen, Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies, Front. Immunol. 11 (2020) 1–13. https://doi.org/10.3389/fimmu.2020.01708.
[10] D.E. Leisman, L. Ronner, R. Pinotti, M.D. Taylor, P. Sinha, C.S. Calfee, A. V. Hirayama, F. Mastroiani, C.J. Turtle, M.O. Harhay, M. Legrand, C.S. Deutschman, Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes, Lancet Respir. Med. 8 (2020) 1233–1244. https://doi.org/10.1016/S2213-2600(20)30404-5.
[11] L. Catteau, N. Dauby, M. Montourcy, E. Bottieau, J. Hautekiet, E. Goetghebeur, S. van Ierssel, E. Duysburgh, H. Van Oyen, C. Wyndham-Thomas, D. Van Beckhoven, K. Bafort, L. Belkhir, N. Bossuyt, P. Caprasse, V. Colombie, P. De Munter, J. Deblonde, D. Delmarcelle, M. Delvallee, R. Demeester, T. Dugernier, X. Holemans, B. Kerzmann, P. Yves Machurot, P. Minette, J.M. Minon, S. Mokrane, C. Nachtergal, S. Noirhomme, D. Piérard, C. Rossi, C. Schirvel, E. Sermijn, F. Staelens, F. Triest, N. Van Goethem, J. Van Praet, A. Vanhoenacker, R. Verstraete, E. Willems, Low-dose hydroxychloroquine therapy and mortality in hospitalised patients with COVID-19: a nationwide observational study of 8075 participants, Int. J. Antimicrob. Agents. 56 (2020). https://doi.org/10.1016/j.ijantimicag.2020.106144.
[12] Verbeke G, Molenberghs G. Linear Mixed Models for Longitudinal Data. Springer Series in Statistics. New-York: Springer-Verlag; 2000.
[13] L.Y.C. Chen, R.L. Hoiland, S. Stukas, C.L. Wellington, M.S. Sekhon, Confronting the controversy: Interleukin-6 and the COVID-19 cytokine storm syndrome, Eur. Respir. J. 56 (2020). https://doi.org/10.1183/13993003.03006-2020.
[14] B.J. Webb, I.D. Peltan, P. Jensen, D. Hoda, B. Hunter, A. Silver, N. Starr, W. Buckel, N. Grisel, E. Hummel, G. Snow, D. Morris, E. Stenehjem, R. Srivastava, S.M. Brown, Clinical criteria for COVID-19-associated hyperinflammatory syndrome: a cohort study, Lancet Rheumatol. 2 (2020) e754–e763. https://doi.org/10.1016/S2665-9913(20)30343-X.
[15] D.M. Del Valle, S. Kim-Schulze, H.H. Huang, N.D. Beckmann, S. Nirenberg, B. Wang, Y. Lavin, T.H. Swartz, D. Madduri, A. Stock, T.U. Marron, H. Xie, M. Patel, K. Tuballes, O. Van Oekelen, A. Rahman, P. Kovatch, J.A. Aberg, E. Schadt, S. Jagannath, M. Mazumdar, A.W. Charney, A. Firpo-Betancourt, D.R. Mendu, J. Jhang, D. Reich, K. Sigel, C. Cordon-Cardo, M. Feldmann, S. Parekh, M. Merad, S. Gnjatic, An inflammatory cytokine signature predicts COVID-19 severity and survival, Nat. Med. 26 (2020) 1636–1643. https://doi.org/10.1038/s41591-020-1051-9.
[16] N. Nishimoto, K. Terao, T. Mima, H. Nakahara, N. Takagi, T. Kakehi, Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease, Blood. 112 (2008) 3959–3964. https://doi.org/10.1182/blood-2008-05-155846.
[17] P. Toniati, S. Piva, M. Cattalini, E. Garrafa, F. Regola, F. Castelli, F. Franceschini, P. Airò, C. Bazzani, E.A. Beindorf, M. Berlendis, M. Bezzi, N. Bossini, M. Castellano, S. Cattaneo, I. Cavazzana, G.B. Contessi, M. Crippa, A. Delbarba, E. De Peri, A. Faletti, M. Filippini, M. Frassi, M. Gaggiotti, R. Gorla, M. Lanspa, S. Lorenzotti, R. Marino, R. Maroldi, M. Metra, A. Matteelli, D. Modina, G. Moioli, G. Montani, M.L. Muiesan, S. Odolini, E. Peli, S. Pesenti, M.C. Pezzoli, I. Pirola, A. Pozzi, A. Proto, F.A. Rasulo, G. Renisi, C. Ricci, D. Rizzoni, G. Romanelli, M. Rossi, M. Salvetti, F. Scolari, L. Signorini, M. Taglietti, G. Tomasoni, L.R. Tomasoni, F. Turla, A. Valsecchi, D. Zani, F. Zuccalà, F. Zunica, E. Focà, L. Andreoli, N. Latronico, Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy, Autoimmun. Rev. 19 (2020) 102568. https://doi.org/10.1016/j.autrev.2020.102568.
[18] B. Furlow, COVACTA trial raises questions about tocilizumab’s benefit in COVID-19, Lancet Rheumatol. 2 (2020) e592. https://doi.org/10.1016/s2665-9913(20)30313-1.
[19] J.H. Stone, M.J. Frigault, N.J. Serling-Boyd, A.D. Fernandes, L. Harvey, A.S. Foulkes, N.K. Horick, B.C. Healy, R. Shah, A.M. Bensaci, A.E. Woolley, S. Nikiforow, N. Lin, M. Sagar, H. Schrager, D.S. Huckins, M. Axelrod, M.D. Pincus, J. Fleisher, C.A. Sacks, M. Dougan, C.M. North, Y.-D. Halvorsen, T.K. Thurber, Z. Dagher, A. Scherer, R.S. Wallwork, A.Y. Kim, S. Schoenfeld, P. Sen, T.G. Neilan, C.A. Perugino, S.H. Unizony, D.S. Collier, M.A. Matza, J.M. Yinh, K.A. Bowman, E. Meyerowitz, A. Zafar, Z.D. Drobni, M.B. Bolster, M. Kohler, K.M. D’Silva, J. Dau, M.M. Lockwood, C. Cubbison, B.N. Weber, M.K. Mansour, Efficacy of Tocilizumab in Patients Hospitalized with Covid-19, N. Engl. J. Med. (2020) 1–12. https://doi.org/10.1056/nejmoa2028836.
[20] Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report, N. Engl. J. Med. (2020) 1–11. https://doi.org/10.1056/nejmoa2021436.
[21] C. Salama, J. Han, L. Yau, W.G. Reiss, B. Kramer, J.D. Neidhart, G.J. Criner, E. Kaplan-Lewis, R. Baden, L. Pandit, M.L. Cameron, J. Garcia-Diaz, V. Chávez, M. Mekebeb-Reuter, ; Ferdinando, L. Menezes, R. Shah, M.F. González-Lara, B. Assman, J. Freedman, S. V Mohan, ; San, J.O. Associates, L. Katz, Tocilizumab in nonventilated patients hospitalized with Covid-19 pneumonia, MedRxiv. (2020) 2020.10.21.20210203. https://doi.org/10.1056/NEJMoa2030340.
[22] B. Maes, C. Bosteels, E. De Leeuw, J. Declercq, K. Van Damme, A. Delporte, B. Demeyere, S. Vermeersch, M. Vuylsteke, J. Willaert, L. Bollé, Y. Vanbiervliet, J. Decuypere, F. Libeer, S. Vandecasteele, I. Peene, B.N. Lambrecht, Erratum: Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial (Trials (2020) 21 468 DOI: 10.1186/s13063-020-04453-5), Trials. 21 (2020) 20–21. https://doi.org/10.1186/s13063-020-04519-4.
[23] V. Azmy, K. Kaman, D. Tang, H. Zhao, C. Dela Cruz, J.E. Topal, M. Malinis, C.C. Price, Cytokine Profiles Before and After Immune Modulation in Hospitalized Patients with COVID-19, J. Clin. Immunol. (2021). https://doi.org/10.1007/s10875-020-00949-6.